Vestipitant
Alternative Names: 597599; GW 597599; GW 597599BLatest Information Update: 24 Oct 2021
At a glance
- Originator GlaxoSmithKline
- Class Antidepressants; Antiemetics; Anxiolytics; Mesylates; Piperazines; Small molecules
- Mechanism of Action Neurokinin 1 antagonists; Neurokinin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anxiety disorders; Dyspepsia; Hearing loss; Major depressive disorder; Postoperative nausea and vomiting; Tinnitus
Most Recent Events
- 29 Feb 2012 Phase-II clinical trials in Postoperative nausea and vomiting in USA (IV)
- 21 May 2007 No development reported - Phase-II for Postoperative nausea and vomiting in USA (unspecified route)
- 25 Nov 2005 Data presented at the 18th Annual Congress of the European College of Neuropsychopharmacology (ECNP-2005) have been added to the adverse events , pharmacokinetics and Anxiety disorders pharmacodynamics sections